NovaBridge Biosciences
About NovaBridge Biosciences
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $632.0K
- Net income
- -$46.3M
- Total assets
- $260.5M
- Market cap
- $190.2M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $190.2M
- Shares outstanding
- 121.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 17, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $46.3M in FY2023.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NovaBridge Biosciences.
Write a review
News about NovaBridge Biosciences
News & sentiment via Polygon.io
